vs
HIVE Digital Technologies Ltd.(HIVE)与PUMA BIOTECHNOLOGY, INC.(PBYI)财务数据对比。点击上方公司名可切换其他公司
HIVE Digital Technologies Ltd.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.2倍($93.1M vs $75.5M),HIVE Digital Technologies Ltd.同比增速更快(218.6% vs 27.7%),过去两年HIVE Digital Technologies Ltd.的营收复合增速更高(102.2% vs 31.3%)
该企业是一家数字化转型与信息技术服务公司,总部位于宾夕法尼亚州匹兹堡,业务覆盖北美、中东、亚洲以及日本地区,为各行各业的企业客户提供专业的IT相关服务支持。
彪马生物技术是一家公开上市的生物制药企业,总部位于美国加利福尼亚州洛杉矶,专注于创新药物研发相关业务,在生物制药领域开展研发与商业化运营。
HIVE vs PBYI — 直观对比
营收规模更大
HIVE
是对方的1.2倍
$75.5M
营收增速更快
HIVE
高出190.8%
27.7%
两年增速更快
HIVE
近两年复合增速
31.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $93.1M | $75.5M |
| 净利润 | $-91.3M | — |
| 毛利率 | -27.1% | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | -98.1% | — |
| 营收同比 | 218.6% | 27.7% |
| 净利润同比 | -234.0% | — |
| 每股收益(稀释后) | $-0.38 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
HIVE
PBYI
| Q4 25 | $93.1M | $75.5M | ||
| Q3 25 | $87.3M | $54.5M | ||
| Q2 25 | $45.6M | $52.4M | ||
| Q1 25 | — | $46.0M | ||
| Q4 24 | $29.2M | $59.1M | ||
| Q3 24 | $22.6M | $80.5M | ||
| Q2 24 | $32.2M | $47.1M | ||
| Q1 24 | — | $43.8M |
净利润
HIVE
PBYI
| Q4 25 | $-91.3M | — | ||
| Q3 25 | $-15.8M | $8.8M | ||
| Q2 25 | $35.0M | $5.9M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | $68.2M | — | ||
| Q3 24 | $80.0K | $20.3M | ||
| Q2 24 | $-18.3M | $-4.5M | ||
| Q1 24 | — | $-4.8M |
毛利率
HIVE
PBYI
| Q4 25 | -27.1% | 69.3% | ||
| Q3 25 | 4.7% | 77.7% | ||
| Q2 25 | -13.6% | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | -43.7% | 76.4% | ||
| Q3 24 | -66.1% | 63.9% | ||
| Q2 24 | -7.4% | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率
HIVE
PBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -5.3% |
净利率
HIVE
PBYI
| Q4 25 | -98.1% | — | ||
| Q3 25 | -18.1% | 16.2% | ||
| Q2 25 | 76.8% | 11.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | 233.2% | — | ||
| Q3 24 | 0.4% | 25.2% | ||
| Q2 24 | -56.7% | -9.6% | ||
| Q1 24 | — | -11.0% |
每股收益(稀释后)
HIVE
PBYI
| Q4 25 | $-0.38 | $0.26 | ||
| Q3 25 | $-0.07 | $0.17 | ||
| Q2 25 | $0.18 | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | $0.52 | $0.40 | ||
| Q3 24 | $0.00 | $0.41 | ||
| Q2 24 | $-0.17 | $-0.09 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $559.3M | $130.3M |
| 总资产 | $624.0M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势,按日历期对齐
现金及短期投资
HIVE
PBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | $40.5M | $101.0M | ||
| Q3 24 | $31.7M | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | — | $107.2M |
总债务
HIVE
PBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益
HIVE
PBYI
| Q4 25 | $559.3M | $130.3M | ||
| Q3 25 | $624.6M | $115.3M | ||
| Q2 25 | $560.5M | $104.7M | ||
| Q1 25 | — | $97.1M | ||
| Q4 24 | $430.9M | $92.1M | ||
| Q3 24 | $275.5M | $71.1M | ||
| Q2 24 | $268.6M | $48.5M | ||
| Q1 24 | — | $51.0M |
总资产
HIVE
PBYI
| Q4 25 | $624.0M | $216.3M | ||
| Q3 25 | $693.0M | $202.9M | ||
| Q2 25 | $628.7M | $194.9M | ||
| Q1 25 | — | $196.2M | ||
| Q4 24 | $478.6M | $213.3M | ||
| Q3 24 | $334.7M | $220.7M | ||
| Q2 24 | — | $205.0M | ||
| Q1 24 | — | $214.1M |
负债/权益比
HIVE
PBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $46.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势,按日历期对齐
经营现金流
HIVE
PBYI
| Q4 25 | $46.0M | $14.4M | ||
| Q3 25 | $-10.6M | $9.7M | ||
| Q2 25 | $10.2M | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $-28.5M | $15.6M | ||
| Q3 24 | $-2.2M | $11.0M | ||
| Q2 24 | $-4.4M | $1.0M | ||
| Q1 24 | — | $11.2M |
自由现金流
HIVE
PBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $-55.5M | $15.6M | ||
| Q3 24 | $-34.7M | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率
HIVE
PBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | -189.9% | 26.4% | ||
| Q3 24 | -153.4% | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度
HIVE
PBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 92.5% | 0.0% | ||
| Q3 24 | 143.9% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率
HIVE
PBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | 0.29× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图